Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients
Received 11 January 2020
Accepted for publication 24 March 2020
Published 30 March 2020 Volume 2020:12 Pages 41—46
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Chuan-Ju Liu
Nur Atik,1,2 Rira Uji Hayati,3 Laniyati Hamijoyo2,4
1Department of Biomedical Sciences, Faculty of Medicine, Padjadjaran University, Bandung, West Java, Indonesia; 2Lupus Study Centre, Immunology Study Group, Padjadjaran University/Hasan Sadikin Hospital, Bandung, West Java, Indonesia; 3Faculty of Medicine, Padjadjaran University, Bandung, West Java, Indonesia; 4Department of Internal Medicine, Padjadjaran University/Hasan Sadikin Hospital, Bandung, West Java, Indonesia
Correspondence: Laniyati Hamijoyo
Department of Internal Medicine, Padjadjaran University/Hasan Sadikin Hospital, Jl. Pasteur 38, Bandung 40161, West Java, Indonesia
Tel +62 222034953
Fax +62 22 2032216
Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with high mortality and morbidity rates, one of the causes of which is cardiovascular events. Dyslipidaemia is known to be one of the main risk factors for cardiovascular disorders and can be induced by steroid therapy, which is commonly administered to SLE patients. This study aimed to determine whether there is a correlation between steroid dose and lipid profile in SLE patients.
Methods: The study was a correlative analytic study with a cross-sectional design. Data were obtained from the Hasan Sadikin Lupus Registry (HSLR) and the medical records of patients registered in the Rheumatology Division, Dr Hasan Sadikin Hospital, Bandung, from 2008 to 2019. Inclusion criteria were SLE patients who had undergone lipid profile examination and received steroid therapy. We excluded patients taking cyclosporine A or statins, and patients treated with steroids for less than a year. A simple random sampling method was performed and Pearson’s correlation test was used for the analysis.
Results: We recruited 41 female patients with an average age of 30.88 ± 9.29 years old. The average dose of steroid in this study was 5.63 mg/day, while the average lipid profile was 177.51 mg/dL, 105.22 mg/dL, 61 mg/dL and 92.98 mg/dL for total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides, respectively. Correlations between steroid dose and total cholesterol (r = 0.375; p = 0.016), and between steroid dose and triglyceride level (r = 0.416; p = 0.007) were statistically significant in SLE patients. However, this study showed no correlation between steroid and HDL level (r = 0.206; p = 0.196) or LDL level (r = 0.308; p = 0.05).
Conclusion: This study showed that the applied steroid dose in SLE patients correlated with total cholesterol and triglyceride levels, but not with HDL or LDL.
Keywords: systemic lupus erythematosus, SLE, dyslipidaemia, steroid therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]